CTBOinactive

CANTABIO PHARMACEUTICALS INC.

Healthcare·Neurology·Pre-clinical
Neurology

CANTABIO PHARMACEUTICALS INC. (CTBO): 5 pipeline candidates · ~3 mo cash runway. Updated within the last hour.

5.4/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.9

3.4 months

Financial Health10.0

0% dilution

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for CANTABIO PHARMACEUTICALS INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$283K

Quarterly Burn

$258K

Runway

3.4 mo

Revenue

—

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Sep 2026
Today~7 mo out
Catalyst within runway

Pipeline (5 candidates)

DrugPhase
cb101Preclinical
cb102Preclinical
cb201Preclinical
cb301Preclinical
cb401Preclinical

Frequently asked questions

How many drug candidates are in CANTABIO PHARMACEUTICALS INC.'s pipeline?

CANTABIO PHARMACEUTICALS INC. (CTBO) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is CANTABIO PHARMACEUTICALS INC.'s lead drug candidate?

CANTABIO PHARMACEUTICALS INC.'s most advanced tracked candidate is cb101 (Preclinical) for Parkinson's Disease.

What is CANTABIO PHARMACEUTICALS INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, CANTABIO PHARMACEUTICALS INC. has approximately 3.4 months of cash runway.

Get the full picture on CANTABIO PHARMACEUTICALS INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar